Ketesse 50 mg/2 ml sol ijf Szlovákia - szlovák - ŠÚKL (Štátny ústav pre kontrolu liečiv)

ketesse 50 mg/2 ml sol ijf

menarini international operations luxembourg s.a., luxembursko - dexketoprofen - 07 - analgetica, antipyretica

Nebilet HCTZ 5 mg/12,5 mg Szlovákia - szlovák - ŠÚKL (Štátny ústav pre kontrolu liečiv)

nebilet hctz 5 mg/12,5 mg

menarini international operations luxembourg s.a., luxembursko - nebivolol a tiazidy - 58 - hypotensiva

Nebilet HCTZ 5 mg/25 mg Szlovákia - szlovák - ŠÚKL (Štátny ústav pre kontrolu liečiv)

nebilet hctz 5 mg/25 mg

menarini international operations luxembourg s.a., luxembursko - nebivolol a tiazidy - 58 - hypotensiva

Dexadol 12,5 mg gro por Szlovákia - szlovák - ŠÚKL (Štátny ústav pre kontrolu liečiv)

dexadol 12,5 mg gro por

menarini international operations luxembourg s.a., luxembursko - dexketoprofén - 07 - analgetica, antipyretica

Ketesse 12,5 mg gro por Szlovákia - szlovák - ŠÚKL (Štátny ústav pre kontrolu liečiv)

ketesse 12,5 mg gro por

menarini international operations luxembourg s.a., luxembursko - dexketoprofen - 07 - analgetica, antipyretica

Ketesse 25 mg gro por Szlovákia - szlovák - ŠÚKL (Štátny ústav pre kontrolu liečiv)

ketesse 25 mg gro por

menarini international operations luxembourg s.a., luxembursko - dexketoprofen - 07 - analgetica, antipyretica

Ketesse 25 mg perorálny roztok vo vrecku Szlovákia - szlovák - ŠÚKL (Štátny ústav pre kontrolu liečiv)

ketesse 25 mg perorálny roztok vo vrecku

menarini international operations luxembourg s.a., luxembursko - dexketoprofen - 07 - analgetica, antipyretica

PULMOCIS Szlovákia - szlovák - ŠÚKL (Štátny ústav pre kontrolu liečiv)

pulmocis

cis bio international, francúzsko - technécium (99mtc) makrosalb - 88 - radiopharmaca

Carvykti Európai Unió - szlovák - EMA (European Medicines Agency)

carvykti

janssen-cilag international nv - ciltacabtagene autoleucel - viacnásobný myelóm - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Imbruvica Európai Unió - szlovák - EMA (European Medicines Agency)

imbruvica

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.